NSCLC (NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check saf…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
AI-Designed vaccine takes on tough lung cancers
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests a personalized vaccine called Microlyvaq™ in 90 people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their tumor's unique features. It is given alongside standard chemothe…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New test aims to predict which lung cancer patients will respond to immunotherapy
Knowledge-focused OngoingThis study collects tumor tissue from 200 people with advanced non-small cell lung cancer to train a new diagnostic platform. The goal is to see if the platform can accurately predict how well a patient will respond to immunotherapy drugs. Participants provide tissue samples, and…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Elephas • Aim: Knowledge-focused
Last updated May 16, 2026 23:51 UTC
-
Tissue collection study aims to build smarter cancer test
Knowledge-focused OngoingThis study collects tumor tissue from about 416 people with various advanced cancers to develop and train a new diagnostic platform called Elephas. The goal is to see how accurately the platform can predict whether a patient will respond to immunotherapy, compared to standard met…
Matched conditions: NSCLC (NON-SMALL CELL LUNG CANCER)
Sponsor: Elephas • Aim: Knowledge-focused
Last updated May 16, 2026 23:47 UTC